As prostate cancer progresses, it becomes increasingly aggressive and can metastasise. In this form, the tumor is difficult to treat, which is reflected in high mortality rates: Worldwide, the malignant disease of the prostate is the second most common cause of cancer death in men.
Roche eyes alternate mode of administration for Ocrevus in MS – Pharmaceutical Technology
Ocrevus as an intravenous (IV) infusion administration was approved by the FDA and the EU for primary progressive and relapsing-remitting MS in 2017 and 2018,
July 13, 2023